Activation of the contact pathway of blood coagulation on the circulating microparticles may explain blood plasma coagulation induced by dilution


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Recent studies have shown that the contact activation of blood coagulation can be initiated on the surface of circulating microparticles–particles formed as a result of the activation or apoptosis of blood cells or endothelial cells. In the present work, by means of a mathematical model, we investigated the mechanism of the activation of contact pathway of blood plasma coagulation. The model describes membrane-dependent reactions of the activation of factors XII and XI with account of the presence of blood plasma inhibitors. All reactions were described by ordinary differential equations integrated by an implicit multistep method. The current mathematical model is based on our previous model of factor XII activation on the platelet surface. The initial model is modified by the addition of factor XI, kallikrein, and blood plasma inhibitors. We show that the amidolytic activity of the contact pathway factors associated with the microparticles is proportional to the concentration of microparticles. In previous studies, an increase in the overall solution amidolytic activity after the dilution of plasma was observed. Computational analysis of the contact pathway activation in the diluted plasma shows that the increase in the activation appears from the dilution of blood plasma inhibitors. Thus, a well-known experimental phenomenon of the hypercoagulability of plasma after dilution can be explained by an increased activation of the blood plasma coagulation through the contact pathway on the circulating microparticles. In addition, the computational analysis reveals that a rapid stop of the contact pathway activation on the microparticles observed in the experiments could be explained by the rapid depletion of the free activation surface.

About the authors

M. A. Chelushkin

Faculty of Physics

Author for correspondence.
Email: ma.chelushkin@physics.msu.ru
Russian Federation, Leninskie Gory 1, build. 2, GSP-1, Moscow, 119991

M. A. Panteleev

Faculty of Physics; Center for Theoretical Problems of Physicochemical Pharmacology; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology; Faculty of Biological and Medical Physics

Email: ma.chelushkin@physics.msu.ru
Russian Federation, Leninskie Gory 1, build. 2, GSP-1, Moscow, 119991; ul. Kosygina 4, Moscow, 119991; ul. Samory Mashela 1, Moscow, 117198; Institutskii per. 9, Dolgoprudnyi, 141700

A. N. Sveshnikova

Faculty of Physics; Center for Theoretical Problems of Physicochemical Pharmacology; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University

Email: ma.chelushkin@physics.msu.ru
Russian Federation, Leninskie Gory 1, build. 2, GSP-1, Moscow, 119991; ul. Kosygina 4, Moscow, 119991; ul. Samory Mashela 1, Moscow, 117198; ul. Ostrovitianova 1, Moscow, 117997

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Pleiades Publishing, Ltd.